tarloxotinib

Ligand id: 9409

Name: tarloxotinib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 140.76
Molecular weight 600.09
XLogP 2.96
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
Is prodrug? Yes
Active form TH-4000E
IUPAC Name
[(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium
International Nonproprietary Names
INN number INN
10229 tarloxotinib bromide
Synonyms
PR610 | tarloxotinib cation | TH-4000
Database Links
CAS Registry No. 1636938-13-0 (source: SciFinder)
PubChem CID 51038316
Search Google for chemical match using the InChIKey MUJMYVFVAWFUJL-SNAWJCMRSA-O
Search Google for chemicals with the same backbone MUJMYVFVAWFUJL
Search PubMed clinical trials tarloxotinib bromide
Search PubMed titles tarloxotinib bromide
Search PubMed titles/abstracts tarloxotinib bromide
Search UniChem for chemical match using the InChIKey MUJMYVFVAWFUJL-SNAWJCMRSA-O
Search UniChem for chemicals with the same backbone MUJMYVFVAWFUJL
Comments
Tarloxotinib (TH-4000) is a hypoxia-activated prodrug (HAP) [1] being developed by Threshold Pharmaceuticals. Delivered as the bromide salt (PubChem CID 51038315) as described in its INN record. The compound undergoes activation selectively within the hypoxic tumour compartment to produce an irreversible pan-ErbB tyrosine-kinase inhibitor, represented by TH-4000E [1]. The 4-nitroimidazole trigger on the tertiary amine side chain facilitates activation. This is one of the first molecularly targeted HAPs to be developed.